Novavax, Inc. (NASDAQ:NVAX) announced it has rescheduled its 4th annual Investor and Analyst Meeting. The Company will host an Investor and Analyst update as part of its third quarter financial results conference call and webcast on Wednesday, November 9, 2016.

“We continue to analyze data from our Resolve clinical trial and map out the clinical path forward for our older adult RSV F Vaccine in the context of our other clinical programs,” said Stanley C. Erck, President and CEO. “We would like to finalize those plans and communicate them at the same time as our third quarter financial results call in early November. We look forward to providing the next steps in our RSV F Vaccine program, as well as an update on the path forward for additional programs in our pipeline and our financial and operating plan, which we will provide as a dedicated part of our November financial results.” (Original Source)

Shares of Novavax closed yesterday at $1.88, down $0.13 or -6.47%. NVAX has a 1-year high of $9.23 and a 1-year low of $1.16. The stock’s 50-day moving average is $5.44 and its 200-day moving average is $6.04.

On the ratings front, NVAX stock has been the subject of a number of recent research reports. In a report issued on September 20, Chardan analyst Keay Nakae maintained a Hold rating on NVAX, with a price target of $1.50, which reflects a potential downside of -20% from last closing price. Separately, on September 19, Citigroup’s Joel Beatty downgraded the stock to Hold and has a price target of $1.50.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Keay Nakae and Joel Beatty have a total average return of -20.7% and 0.1% respectively. Nakae has a success rate of 31% and is ranked #4021 out of 4190 analysts, while Beatty has a success rate of 47% and is ranked #2691.

The street is mostly Neutral on NVAX stock. Out of 8 analysts who cover the stock, 6 suggest a Hold rating and 2 recommend to Buy the stock. The 12-month average price target assigned to the stock is $13.50, which implies an upside of 618.1% from current levels.

Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants. Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus (EBOV).